Current treatment strategies for inhibiting mTOR in cancer

Trends in Pharmacological Sciences

Volumn 36, Issue 2, 2015, Pages 124-135

  Chiarini, Francesca ^a,b   Evangelisti, Camilla ^a,b   McCubrey, James A ^c   Martelli, Alberto M ^d  

^a CNR   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c EAST CAROLINA UNIVERSITY   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

ATP competitive mTOR inhibitors; dual PI3K mTOR inhibitors; rapalogs; rapamycin; translation

Indexed keywords

2 AMINO 8 [4 (2 HYDROXYETHOXY)CYCLOHEXYL] 6 (6 METHOXY 3 PYRIDINYL) 4 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 3 (2 AMINO 5 BENZOXAZOLYL) 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 4 AMINE; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; 8 (6 METHOXY 3 PYRIDINYL) 3 METHYL 1 [4 (1 PIPERAZINYL) 3 (TRIFLUOROMETHYL)PHENYL] 1H IMIDAZO[4,5 C]QUINOLIN 2(3H) ONE; ANTIESTROGEN; APITOLISIB; AZD 2014; AZD 8055; CC 115; CC 223; CYCLOPHOSPHAMIDE; DACTOLISIB; DEXAMETHASONE; DOXORUBICIN; DS 7423; EVEROLIMUS; GEDATOLISIB; HYDROXYCHLOROQUINE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NAVELBINE; OMIPALISIB; RAPAMYCIN; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VOXTALISIB; VS 5584; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

5' UNTRANSLATED REGION; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; BRAF GENE; BREAST CANCER; CANCER REGRESSION; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; COWDEN SYNDROME; DIARRHEA; DOWN REGULATION; DRUG APPROVAL; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; ENDOMETRIUM CANCER; ENZYME ACTIVITY; ENZYME REGULATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EWING SARCOMA; FATIGUE; GENE; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY METASTASIS; LEUKEMIA; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; NAUSEA; NEXT GENERATION SEQUENCING; NF2 GENE; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOGENE K RAS; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PERSONALIZED MEDICINE; PEUTZ JEGHERS SYNDROME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TRANSLATIONAL RESEARCH; TUBEROUS SCLEROSIS; VOMITING; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; TOR SERINE-THREONINE KINASES;

EID: 84922210268     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2014.11.004     Document Type: Review

References (108)

1. M. Laplante, and D.M. Sabatini mTOR signaling in growth control and disease Cell 149 2012 274 293
2. R.T. Abraham PI 3-kinase related kinases: 'big' players in stress-induced signaling pathways DNA Repair (Amst.) 3 2004 883 887
3. M. Shimobayashi, and M.N. Hall Making new contacts: the mTOR network in metabolism and signalling crosstalk Nat. Rev. Mol. Cell Biol. 15 2014 155 162
4. C. Ierano CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells Cell Death Dis. 5 2014 e1310
5. S. Sengupta Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress Mol. Cell 40 2010 310 322
6. C.C. Thoreen A unifying model for mTORC1-mediated regulation of mRNA translation Nature 485 2012 109 113
7. H.X. Yuan Nutrient sensing, metabolism, and cell growth control Mol. Cell 49 2013 379 387
8. C. Chauvin Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program Oncogene 33 2014 474 483
9. E.A. Dunlop, and A.R. Tee mTOR and autophagy: a dynamic relationship governed by nutrients and energy Semin. Cell Dev. Biol. 2014 10.1016/j.semcdb.2014.08.006 Published online August 23, 2014
10. S. Alers The incredible ULKs Cell Commun. Signal. 10 2012 7
11. V. Zinzalla Activation of mTORC2 by association with the ribosome Cell 144 2011 757 768
12. E.M. Beauchamp, and L.C. Platanias The evolution of the TOR pathway and its role in cancer Oncogene 32 2013 3923 3932
13. B. Shuch Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer J. Urol. 190 2013 1990 1998
14. J. Liang, and G.B. Mills AMPK: a contextual oncogene or tumor suppressor? Cancer Res. 73 2013 2929 2935
15. P. Curatolo Tuberous sclerosis Lancet 372 2008 657 668
16. P.B. Crino The tuberous sclerosis complex N. Engl. J. Med. 355 2006 1345 1356
17. D.N. Franz, and B.D. Weiss Molecular therapies for tuberous sclerosis and neurofibromatosis Curr. Neurol. Neurosci. Rep. 12 2012 294 301
18. C.M. Johannessen TORC1 is essential for NF1-associated malignancies Curr. Biol. 18 2008 56 62
19. C.M. Johannessen The NF1 tumor suppressor critically regulates TSC2 and mTOR Proc. Natl. Acad. Sci. U.S.A. 102 2005 8573 8578
20. R.D. Schroeder NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations Oncotarget 5 2014 67 77
21. J.A. McCubrey Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response Oncotarget 3 2012 954 987
22. M. Martini PI3K/AKT signaling pathway and cancer: an updated review Ann. Med. 46 2014 372 383
23. B.D. Hopkins PTEN function: the long and the short of it Trends Biochem. Sci. 39 2014 183 190
24. D.G. Hardie, and D.R. Alessi LKB1 and AMPK and the cancer-metabolism link - ten years after BMC Biol. 11 2013 36
25. P. Seshacharyulu Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer Cancer Lett. 335 2013 9 18
26. D.D. Sarbassov Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB Mol. Cell 22 2006 159 168
27. A. Efeyan, and D.M. Sabatini mTOR and cancer: many loops in one pathway Curr. Opin. Cell Biol. 22 2010 169 176
28. J. Li Rapamycin: one drug, many effects Cell Metab. 19 2014 373 379
29. D.W. Lamming Rapalogs and mTOR inhibitors as anti-aging therapeutics J. Clin. Invest. 123 2013 980 989
30. M. Guba Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat. Med. 8 2002 128 135
31. T.F. Cloughesy Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma PLoS Med. 5 2008 e8
32. D. Benjamin Rapamycin passes the torch: a new generation of mTOR inhibitors Nat. Rev. Drug Discov. 10 2011 868 880
33. G. Hudes Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N. Engl. J. Med. 356 2007 2271 2281
34. G. Hess Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma J. Clin. Oncol. 27 2009 3822 3829
35. G. Santulli, and H. Totary-Jain Tailoring mTOR-based therapy: molecular evidence and clinical challenges Pharmacogenomics 14 2013 1517 1526
36. A. Kapoor, and R.A. Figlin Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma Cancer 115 2009 3618 3630
37. D.A. Krueger Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis N. Engl. J. Med. 363 2010 1801 1811
38. J.C. Yao Everolimus for advanced pancreatic neuroendocrine tumors N. Engl. J. Med. 364 2011 514 523
39. J. Baselga Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N. Engl. J. Med. 366 2012 520 529
40. J. Tamburini Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia Blood 114 2009 1618 1627
41. F. Chiarini Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia Cancer Res. 70 2010 8097 8107
42. S.A. Kang mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin Science 341 2013 1236566
43. A.M. Martelli Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway Leukemia 25 2011 1064 1079
44. A.M. Martelli Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment Oncotarget 3 2012 371 394
45. A. Carracedo Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer J. Clin. Invest. 118 2008 3065 3074
46. S. Chandarlapaty AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity Cancer Cell 19 2011 58 71
47. J. Bertacchini Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis Leukemia 28 2014 2197 2205
48. P.P. Hsu The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling Science 332 2011 1317 1322
49. K.E. O'Reilly mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res. 66 2006 1500 1508
50. J. Tabernero Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a Phase I tumor pharmacodynamic study in patients with advanced solid tumors J. Clin. Oncol. 26 2008 1603 1610
51. D.A. Gewirtz The four faces of autophagy: implications for cancer therapy Cancer Res. 74 2014 647 651
52. K. Bray Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition PLoS ONE 7 2012 e41831
53. Y. Wang MTOR inhibition attenuates DNA damage and apoptosis through autophagy-mediated suppression of CREB1 Autophagy 9 2013 2069 2086
54. X. Xie Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma PLoS ONE 8 2013 e55096
55. R. Rangwala Combined mTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma Autophagy 10 2014 1391 1402
56. K. Margolin CCI-779 in metastatic melanoma: a Phase II trial of the California Cancer Consortium Cancer 104 2005 1045 1048
57. G. Iyer Genome sequencing identifies a basis for everolimus sensitivity Science 338 2012 221
58. M.A. Lopez-Lago Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling Mol. Cell. Biol. 29 2009 4235 4249
59. N. Wagle Activating mTOR mutations in a patient with an extraordinary response on a Phase I trial of everolimus and pazopanib Cancer Discov. 4 2014 546 553
60. J. Hou Targeting Mnks for cancer therapy Oncotarget 3 2012 118 131
61. J.K. Altman Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responses Mol. Pharmacol. 78 2010 778 784
62. C. Wang Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer Cell Cycle 12 2013 1999 2010
63. A.M. Martelli PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy Adv. Biol. Regul. 52 2012 214 227
64. F. Di Nicolantonio Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus J. Clin. Invest. 120 2010 2858 2866
65. J.D. Valentino Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors Clin. Cancer Res. 20 2014 1212 1222
66. T. Sato Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer Oncogene 29 2010 2746 2752
67. M. Gerlinger Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N. Engl. J. Med. 366 2012 883 892
68. B.C. Grabiner A diverse array of cancer-associated mTOR mutations are hyperactivating and can predict rapamycin sensitivity Cancer Discov. 4 2014 554 563
69. B. Hassan Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors Oncotarget 5 2014 8544 8557
70. M.C. Lorenz, and J. Heitman TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin J. Biol. Chem. 270 1995 27531 27537
71. J. Chen Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue Proc. Natl. Acad. Sci. U.S.A. 92 1995 4947 4951
72. N. Daver A Phase I/II study of Hyper-CVAD plus everolimus in patients with relapsed/refractory acute lymphoblastic leukemia Blood 122 2013 3916
73. F. Andre Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled Phase 3 trial Lancet Oncol. 15 2014 580 591
74. Q.W. Fan A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma Cancer Cell 9 2006 341 349
75. R. Dienstmann Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors Mol. Cancer Ther. 13 2014 1021 1031
76. N. Chapuis Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia Clin. Cancer Res. 16 2010 5424 5435
77. F. Yang Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma PLoS ONE 8 2013 e59879
78. C.R. Gil del Alcazar Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma Clin. Cancer Res. 20 2014 1235 1248
79. S. Ogita, and P. Lorusso Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs Target. Oncol. 6 2011 103 117
80. A. Kim Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer Int. J. Cancer 133 2013 984 996
81. C. Shepherd PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response Leukemia 27 2013 650 660
82. N. Ilic PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis Proc. Natl. Acad. Sci. U.S.A. 108 2011 E699 E708
83. N. Pallet, and C. Legendre Adverse events associated with mTOR inhibitors Expert Opin. Drug Saf. 12 2013 177 186
84. B. Markman Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors Ann. Oncol. 23 2012 2399 2408
85. V. Nelson Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer Expert Opin. Investig. Drugs 22 2013 715 722
86. M.E. Feldman Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 PLoS Biol. 7 2009 e38
87. C. Evangelisti Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia Leukemia 25 2011 781 791
88. L. Willems The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia Leukemia 26 2012 1195 1202
89. M.R. Janes Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia Leukemia 27 2013 586 594
90. C.E. Atreya Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer Invest. New Drugs 30 2012 2219 2225
91. V.S. Rodrik-Outmezguine mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling Cancer Discov. 1 2011 248 259
92. G.S. Ducker Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors Oncogene 33 2014 1590 1600
93. T. Alain eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies Cancer Res. 72 2012 6468 6476
94. Y. Martineau Pancreatic tumours escape from translational control through 4E-BP1 loss Oncogene 33 2014 1367 1374
95. S. Mallya Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1 PLoS ONE 9 2014 e88865
96. A. Naing Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma Br. J. Cancer 107 2012 1093 1099
97. M.R. Janes Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor Nat. Med. 16 2010 205 213
98. O.H. Yilmaz PTEN dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells Nature 441 2006 475 482
99. M.G. Francipane, and E. Lagasse Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1 Oncotarget 4 2013 1948 1962
100. A. Dubrovska Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma Clin. Cancer Res. 16 2010 5692 5702
101. M.T. Mueller Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer Gastroenterology 137 2009 1102 1113
102. J. Kahn The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells Neuro Oncol. 16 2014 29 37
103. R.C. Russell An emerging role for TOR signaling in mammalian tissue and stem cell physiology Development 138 2011 3343 3356
104. J.D. Ochocki, and M.C. Simon Nutrient-sensing pathways and metabolic regulation in stem cells J. Cell Biol. 203 2013 23 33
105. R. Simon, and S. Roychowdhury Implementing personalized cancer genomics in clinical trials Nat. Rev. Drug Discov. 12 2013 358 369
106. C. Toniatti Oncology drug discovery: planning a turnaround Cancer Discov. 4 2014 397 404
107. I. Krop Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors J. Clin. Oncol. 30 2012 2307 2313
108. M. Kraus Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera PLoS ONE 7 2012 e37207